{
  "StudyFieldsResponse":{
    "APIVrs":"1.01.05",
    "DataVrs":"2024:05:15 23:48:06.626",
    "Expression":"EGFR AND AREA[OverallStatus][RECRUITING,ACTIVE]",
    "NStudiesAvail":495057,
    "NStudiesFound":486,
    "MinRank":1,
    "MaxRank":50,
    "NStudiesReturned":50,
    "FieldList":[
      "NCTId",
      "BriefTitle",
      "Condition",
      "OverallStatus"
    ],
    "StudyFields":[
      {
        "Rank":1,
        "NCTId":[
          "NCT03638167"
        ],
        "BriefTitle":[
          "EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors"
        ],
        "Condition":[
          "Central Nervous System Tumor, Pediatric",
          "Glioma",
          "Ependymoma",
          "Medulloblastoma",
          "Germ Cell Tumor",
          "Atypical Teratoid/Rhabdoid Tumor",
          "Primitive Neuroectodermal Tumor",
          "Choroid Plexus Carcinoma",
          "Pineoblastoma"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":2,
        "NCTId":[
          "NCT03344250"
        ],
        "BriefTitle":[
          "Phase I EGFR BATs in Newly Diagnosed Glioblastoma"
        ],
        "Condition":[
          "Glioblastoma",
          "Glioblastoma Multiforme"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":3,
        "NCTId":[
          "NCT01754025"
        ],
        "BriefTitle":[
          "INHERIT EGFR - Studying Germline EGFR Mutations"
        ],
        "Condition":[
          "Lung Cancer"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":4,
        "NCTId":[
          "NCT04908956"
        ],
        "BriefTitle":[
          "Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)"
        ],
        "Condition":[
          "NSCLC Stage IV",
          "EGFR Gene Mutation"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":5,
        "NCTId":[
          "NCT03269526"
        ],
        "BriefTitle":[
          "BATs Treatment for Pancreatic Cancer, Phase Ib/II"
        ],
        "Condition":[
          "Locally Advanced Pancreatic Adenocarcinoma",
          "Metastatic Pancreatic Adenocarcinoma"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":6,
        "NCTId":[
          "NCT04206072"
        ],
        "BriefTitle":[
          "D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC"
        ],
        "Condition":[
          "Non-Small Cell Lung Cancer",
          "EGFR Gene Mutation"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":7,
        "NCTId":[
          "NCT04137536"
        ],
        "BriefTitle":[
          "A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer"
        ],
        "Condition":[
          "Pancreatic Cancer",
          "Advanced Pancreatic Cancer",
          "Pancreatic Adenocarcinoma",
          "Pancreatic Neoplasms"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":8,
        "NCTId":[
          "NCT03865511"
        ],
        "BriefTitle":[
          "MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib"
        ],
        "Condition":[
          "Non-small Cell Lung Cancer"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":9,
        "NCTId":[
          "NCT03994393"
        ],
        "BriefTitle":[
          "Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease."
        ],
        "Condition":[
          "EGFR Mutant Advanced Non Small Cell Lung Cancer"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":10,
        "NCTId":[
          "NCT03066206"
        ],
        "BriefTitle":[
          "Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC"
        ],
        "Condition":[
          "EGFR Exon 20 Mutation",
          "ERBB2 Gene Mutation",
          "Recurrent Lung Non-Small Cell Carcinoma",
          "Stage IV Non-Small Cell Lung Cancer AJCC v7"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":11,
        "NCTId":[
          "NCT05258279"
        ],
        "BriefTitle":[
          "Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations"
        ],
        "Condition":[
          "Non-squamous Non-small-cell Lung Cancer",
          "EGFR Activating Mutation"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":12,
        "NCTId":[
          "NCT03974022"
        ],
        "BriefTitle":[
          "Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)"
        ],
        "Condition":[
          "Non-Small Cell Lung Cancer"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":13,
        "NCTId":[
          "NCT03908788"
        ],
        "BriefTitle":[
          "Detection of the Emergence of RAS (Rat Sarcoma Viral Oncogene Homolog) Mutations in Circulating DNA (Deoxyribonucleic Acid) in Patients With mCRC (Metastatic Colorectal Cancer) During Treatment With Anti-EGFR (Epidermal Growth Factor Receptor) Therapy"
        ],
        "Condition":[
          "Metastatic Colorectal Cancer"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":14,
        "NCTId":[
          "NCT04085315"
        ],
        "BriefTitle":[
          "Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer"
        ],
        "Condition":[
          "Lung Cancer Metastatic",
          "EGFR Gene Mutation"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":15,
        "NCTId":[
          "NCT06391944"
        ],
        "BriefTitle":[
          "JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations"
        ],
        "Condition":[
          "Local Advanced or Metastatic NSCLC",
          "Harboring EGFR Common Mutation"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":16,
        "NCTId":[
          "NCT05338970"
        ],
        "BriefTitle":[
          "HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy"
        ],
        "Condition":[
          "Nonsquamous Non-small Cell Lung Cancer",
          "EGFR L858R",
          "EGFR Exon 19 Deletion"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":17,
        "NCTId":[
          "NCT05120362"
        ],
        "BriefTitle":[
          "A Study to Evaluate JAK Inhibitor Cream in EGFR-inhibitor-induced Skin Rash"
        ],
        "Condition":[
          "Acneiform Eruptions"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":18,
        "NCTId":[
          "NCT03333343"
        ],
        "BriefTitle":[
          "Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC"
        ],
        "Condition":[
          "EGFR-mutant Non-small Cell Lung Cancer"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":19,
        "NCTId":[
          "NCT04862780"
        ],
        "BriefTitle":[
          "(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC"
        ],
        "Condition":[
          "Lung Neoplasms",
          "Carcinoma, Non-Small-Cell Lung",
          "Respiratory Tract Neoplasms",
          "Neoplasms",
          "Neoplasms by Site",
          "Lung Diseases",
          "Respiratory Tract Disease",
          "Carcinoma, Bronchogenic",
          "Bronchial Neoplasms",
          "Adenocarcinoma",
          "Carcinoma",
          "Neoplasms by Histologic Type",
          "Neoplasms, Nerve Tissue",
          "EGFR T790M",
          "EGFR C797S",
          "EGFR L858R",
          "EGFR Gene Mutation",
          "EGF-R Positive Non-Small Cell Lung Cancer",
          "EGFR Exon 19 Deletion",
          "EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance",
          "EGFR Activating Mutation",
          "Protein Kinase Inhibitors",
          "Antineoplastic Agents",
          "Thoracic Neoplasms"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":20,
        "NCTId":[
          "NCT03567642"
        ],
        "BriefTitle":[
          "A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers"
        ],
        "Condition":[
          "Lung Cancer"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":21,
        "NCTId":[
          "NCT04233021"
        ],
        "BriefTitle":[
          "Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation"
        ],
        "Condition":[
          "Non Small Cell Lung Cancer Metastatic",
          "Leptomeningeal Metastasis",
          "Brain Metastases",
          "EGFR Activating Mutation"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":22,
        "NCTId":[
          "NCT04538664"
        ],
        "BriefTitle":[
          "A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions"
        ],
        "Condition":[
          "Carcinoma, Non-Small-Cell Lung"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":23,
        "NCTId":[
          "NCT03122717"
        ],
        "BriefTitle":[
          "Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer"
        ],
        "Condition":[
          "Non-Small Cell Lung Cancer"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":24,
        "NCTId":[
          "NCT02493582"
        ],
        "BriefTitle":[
          "The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR"
        ],
        "Condition":[
          "Adenocarcinoma of Lung"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":25,
        "NCTId":[
          "NCT03392246"
        ],
        "BriefTitle":[
          "A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer"
        ],
        "Condition":[
          "Non-small Cell Lung Cancer"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":26,
        "NCTId":[
          "NCT02633189"
        ],
        "BriefTitle":[
          "Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer"
        ],
        "Condition":[
          "Non-squamous Non-small Cell Lung Cancer"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":27,
        "NCTId":[
          "NCT04619004"
        ],
        "BriefTitle":[
          "HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer"
        ],
        "Condition":[
          "Non-Small Cell Lung Cancer Metastatic",
          "Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":28,
        "NCTId":[
          "NCT03732352"
        ],
        "BriefTitle":[
          "18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma"
        ],
        "Condition":[
          "EGFR Gene Amplification",
          "EGFR Gene Mutation",
          "Glioblastoma",
          "Recurrent Glioblastoma",
          "Supratentorial Glioblastoma",
          "TP53 wt Allele"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":29,
        "NCTId":[
          "NCT03810807"
        ],
        "BriefTitle":[
          "Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer"
        ],
        "Condition":[
          "Metastatic Non-small Cell Lung Cancer"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":30,
        "NCTId":[
          "NCT04609319"
        ],
        "BriefTitle":[
          "Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review"
        ],
        "Condition":[
          "Lung Cancer"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":31,
        "NCTId":[
          "NCT02438722"
        ],
        "BriefTitle":[
          "S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer"
        ],
        "Condition":[
          "Recurrent Non-Small Cell Lung Carcinoma",
          "Stage IV Non-Small Cell Lung Cancer"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":32,
        "NCTId":[
          "NCT01815749"
        ],
        "BriefTitle":[
          "Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma"
        ],
        "Condition":[
          "Adult Grade III Lymphomatoid Granulomatosis",
          "Cutaneous B-cell Non-Hodgkin Lymphoma",
          "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
          "Intraocular Lymphoma",
          "Nodal Marginal Zone B-cell Lymphoma",
          "Post-transplant Lymphoproliferative Disorder",
          "Recurrent Adult Burkitt Lymphoma",
          "Recurrent Adult Diffuse Large Cell Lymphoma",
          "Recurrent Adult Diffuse Mixed Cell Lymphoma",
          "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
          "Recurrent Adult Grade III Lymphomatoid Granulomatosis",
          "Recurrent Adult Immunoblastic Large Cell Lymphoma",
          "Recurrent Adult Lymphoblastic Lymphoma",
          "Recurrent Grade 1 Follicular Lymphoma",
          "Recurrent Grade 2 Follicular Lymphoma",
          "Recurrent Grade 3 Follicular Lymphoma",
          "Recurrent Mantle Cell Lymphoma",
          "Recurrent Marginal Zone Lymphoma",
          "Recurrent Small Lymphocytic Lymphoma",
          "Refractory Hairy Cell Leukemia",
          "Small Intestine Lymphoma",
          "Splenic Marginal Zone Lymphoma",
          "Testicular Lymphoma",
          "Waldenström Macroglobulinemia"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":33,
        "NCTId":[
          "NCT05146219"
        ],
        "BriefTitle":[
          "Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation"
        ],
        "Condition":[
          "NSCLC",
          "EGFR Activating Mutation",
          "Brain Metastases",
          "Leptomeningeal Metastasis"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":34,
        "NCTId":[
          "NCT03391843"
        ],
        "BriefTitle":[
          "Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer"
        ],
        "Condition":[
          "Rectal Cancer Stage III"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":35,
        "NCTId":[
          "NCT03969823"
        ],
        "BriefTitle":[
          "Whole Genomic Landscape of Advanced EGFR-mutant NSCLC"
        ],
        "Condition":[
          "Locally Advanced or Metastatic NSCLC"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":36,
        "NCTId":[
          "NCT03667820"
        ],
        "BriefTitle":[
          "Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC"
        ],
        "Condition":[
          "Non-small Cell Lung Cancer (NSCLC)"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":37,
        "NCTId":[
          "NCT03804580"
        ],
        "BriefTitle":[
          "First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer"
        ],
        "Condition":[
          "Lung Cancer"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":38,
        "NCTId":[
          "NCT04391283"
        ],
        "BriefTitle":[
          "First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting"
        ],
        "Condition":[
          "Carcinoma, Non-Small-Cell Lung"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":39,
        "NCTId":[
          "NCT03065387"
        ],
        "BriefTitle":[
          "Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation"
        ],
        "Condition":[
          "Advanced Malignant Solid Neoplasm",
          "EGFR Gene Amplification",
          "EGFR Gene Mutation",
          "ERBB2 Gene Amplification",
          "ERBB2 Gene Mutation",
          "ERBB3 Gene Mutation",
          "ERBB4 Gene Mutation",
          "KRAS Gene Mutation",
          "Metastatic Malignant Solid Neoplasm",
          "Refractory Malignant Solid Neoplasm"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":40,
        "NCTId":[
          "NCT02496663"
        ],
        "BriefTitle":[
          "Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor"
        ],
        "Condition":[
          "Metastatic Lung Non-Small Cell Carcinoma",
          "Recurrent Lung Non-Small Cell Carcinoma",
          "Stage IV Lung Cancer AJCC v8"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":41,
        "NCTId":[
          "NCT03471364"
        ],
        "BriefTitle":[
          "Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash"
        ],
        "Condition":[
          "Malignant Neoplasm"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":42,
        "NCTId":[
          "NCT02856893"
        ],
        "BriefTitle":[
          "Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)"
        ],
        "Condition":[
          "NSCLC"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":43,
        "NCTId":[
          "NCT05241873"
        ],
        "BriefTitle":[
          "(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations"
        ],
        "Condition":[
          "Lung Neoplasm Malignant",
          "Carcinoma, Non-Small-Cell Lung",
          "Respiratory Tract Neoplasms",
          "Neoplasms",
          "Neoplasms by Site",
          "Lung Diseases",
          "Respiratory Tract Disease",
          "Carcinoma, Bronchogenic",
          "Bronchial Neoplasms",
          "Adenocarcinoma",
          "Carcinoma",
          "Neoplasms by Histologic Type",
          "EGFR Exon 20 Mutation",
          "EGFR Exon 20 Insertion Mutation",
          "EGFR Activating Mutation",
          "Antineoplastic Agents",
          "Metastatic Lung Cancer",
          "Brain Metastases",
          "EGFR-mutated NSCLC",
          "EGFR Atypical Mutations, Including G719X and L861Q"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":44,
        "NCTId":[
          "NCT06046495"
        ],
        "BriefTitle":[
          "A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer"
        ],
        "Condition":[
          "Non-Small Cell Lung Cancer"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":45,
        "NCTId":[
          "NCT06303167"
        ],
        "BriefTitle":[
          "Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)"
        ],
        "Condition":[
          "Advanced Lymphoma",
          "Advanced Malignant Solid Neoplasm",
          "Hematopoietic and Lymphoid Cell Neoplasm",
          "Refractory Lymphoma",
          "Refractory Malignant Solid Neoplasm",
          "Refractory Multiple Myeloma"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":46,
        "NCTId":[
          "NCT04545710"
        ],
        "BriefTitle":[
          "Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance"
        ],
        "Condition":[
          "Lung Cancer"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":47,
        "NCTId":[
          "NCT05712902"
        ],
        "BriefTitle":[
          "DZD9008 in Pretreated Lung Cancer Patients With EGFR Exon20 Insertion Mutation"
        ],
        "Condition":[
          "Non-Small Cell Lung Cancer"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":48,
        "NCTId":[
          "NCT04141644"
        ],
        "BriefTitle":[
          "PhIb Study Evaluating Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC"
        ],
        "Condition":[
          "Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":49,
        "NCTId":[
          "NCT02520778"
        ],
        "BriefTitle":[
          "Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer"
        ],
        "Condition":[
          "Advanced Lung Non-Squamous Non-Small Cell Carcinoma",
          "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma",
          "Stage III Lung Non-Small Cell Cancer AJCC v7",
          "Stage IIIA Lung Non-Small Cell Cancer AJCC v7",
          "Stage IIIB Lung Non-Small Cell Cancer AJCC v7",
          "Stage IV Lung Non-Small Cell Cancer AJCC v7"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      },{
        "Rank":50,
        "NCTId":[
          "NCT03758287"
        ],
        "BriefTitle":[
          "Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative"
        ],
        "Condition":[
          "Non-small Cell Lung Cancer"
        ],
        "OverallStatus":[
          "Active, not recruiting"
        ]
      }
    ]
  }
}